Revenue Agenda
  • Investing
  • Latest News
  • Editor’s Pick
  • Economy
  • Investing
  • Latest News
  • Editor’s Pick
  • Economy
No Result
View All Result
Revenue Agenda
No Result
View All Result
Home Latest News

Sanders targets pharma CEOs to testify in Senate, but some see ‘retaliation’ for lawsuit against Biden admin

by
January 20, 2024
in Latest News
0
Sanders targets pharma CEOs to testify in Senate, but some see ‘retaliation’ for lawsuit against Biden admin
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter
Read this article for free!
Plus get unlimited access to thousands of articles, videos and more with your free account!
Please enter a valid email address.
By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the content, check your email and follow the instructions provided.

Sen. Bernie Sanders, I-Vt., announced this week he plans to hold a vote on Jan. 31 to subpoena the CEOs of two big Pharma companies for a hearing on drug pricing in front of the Health, Education Labor & Pensions (HELP) Committee after they refused to testify last year.

The subpoenas for Johnson & Johnson CEO Joaquin Duato and Merck CEO Robert Davis would have them testify about why their costs for medicine are ‘substantially higher’ compared to other countries, the announcement said. 

But some executives see the pending subpoenas as a form of retaliation for a court battle over Medicare price negotiations.

‘It is absolutely unacceptable that the CEOs of Johnson & Johnson and Merck have refused an invitation by a majority of members on the HELP Committee to appear before Congress about the outrageously high price of prescription drugs,’ Sanders said. ‘These CEOs may make tens of millions of dollars in compensation. The pharmaceutical companies they run may make billions in profits.’

In November, Sanders requested Duato and Davis for testimonies on drug pricing, but they insisted that a ‘senior pharmaceutical executive best positioned to address and provide Johnson & Johnson’s position regarding the issues’ should instead appear, according to a letter Johnson & Johnson attorney Brian D. Smith sent to Sanders this week in response to the subpoena announcement. 

‘Johnson & Johnson offered to make available for the hearing the senior pharmaceutical executive best positioned to address and provide Johnson & Johnson’s position regarding the issues posed in your invitation letter,’ Smith wrote. ‘Throughout these discussions, Johnson & Johnson has also made clear its concerns with the direction the Committee is taking with the hearing, including the reasons that the company’s chief executive is not the appropriate witness for this hearing. We appreciate the opportunity to reiterate the concerns that we have previously conveyed to your staff over the past three months, and we urge you to consider permitting the Committee to hear from the appropriate executive for these topics.’

The two Pharma companies, alongside others, are currently suing to freeze Medicare drug price negotiation under Biden’s Inflation Reduction Act. Merck Executive Vice President Jennifer Zachary also sent a letter to Sanders this week suggesting the request to have the CEOs testify in front of the Senate panel is a form of ‘retaliation’ for the ongoing lawsuit.

 ‘We appreciate that many Committee members have expressed their disagreement with our lawsuit, and we respect their good-faith views. That said, your public criticisms of the Companies for challenging the IRA and comments regarding hearing witnesses indicate that the invitations to testify have been extended as retaliation for the Companies’ exercise of their constitutional right to seek relief in court,’ Zachary wrote. 

Joe Grogan, who served as a domestic policy advisor to former President Trump, told Fox News Digital in an interview that ‘CEOs are not the subject matter experts in the company who can explain all the different aspects of the pharmaceutical supply chain’ and negotiations with other governments.

‘To put a fine point on it, it’s completely un-American,’ Grogan said. ‘I mean, these companies have every right to avail themselves of the courts, they have every right to sue and to be for him to target these three companies is not a coincidence.’

This post appeared first on FOX NEWS
Previous Post

Haley’s race arguments try to reconcile U.S. history with GOP politics

Next Post

Former GOP presidential candidate Tim Scott endorses Trump for nomination

Next Post
Former GOP presidential candidate Tim Scott endorses Trump for nomination

Former GOP presidential candidate Tim Scott endorses Trump for nomination

  • Trending
  • Comments
  • Latest
Top 10 Potash Countries by Production (Updated 2024)

Top 10 Potash Countries by Production (Updated 2024)

August 21, 2024
Top 10 Phosphate Countries by Production (Updated 2024)

Top 10 Phosphate Countries by Production (Updated 2024)

August 1, 2024
7 Biggest Lithium-mining Companies in 2024

7 Biggest Lithium-mining Companies in 2024

September 18, 2024
Top 10 Uranium-producing Countries (Updated 2024)

Top 10 Uranium-producing Countries (Updated 2024)

November 6, 2024
Rio Silver to Complete 5:1 Consolidation

Rio Silver to Complete 5:1 Consolidation

0
New Hampshire Gov. Sununu signs $15.2B ‘miracle’ budget into law

New Hampshire Gov. Sununu signs $15.2B ‘miracle’ budget into law

0

Pennsylvania House clears tax credits for new teachers, nurses, police officers

0
Evers signs bipartisan sales tax bill aimed at sparing Milwaukee from bankruptcy

Evers signs bipartisan sales tax bill aimed at sparing Milwaukee from bankruptcy

0
Rio Silver to Complete 5:1 Consolidation

Rio Silver to Complete 5:1 Consolidation

June 28, 2025
Market Pain, Strategic Gain: Pilbara Minerals’ Dale Henderson on Today’s Lithium Paradox

Market Pain, Strategic Gain: Pilbara Minerals’ Dale Henderson on Today’s Lithium Paradox

June 28, 2025
Platinum Price Surges to 11 Year High, Breaks US$1,400

Platinum Price Surges to 11 Year High, Breaks US$1,400

June 28, 2025
Freegold Ventures Limited – Results of the Annual General and Special Meeting

Freegold Ventures Limited – Results of the Annual General and Special Meeting

June 28, 2025
Enter Your Information Below To Receive Trading Ideas and Latest News

Error: Contact form not found.

Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Recent News

Rio Silver to Complete 5:1 Consolidation

Rio Silver to Complete 5:1 Consolidation

June 28, 2025
Market Pain, Strategic Gain: Pilbara Minerals’ Dale Henderson on Today’s Lithium Paradox

Market Pain, Strategic Gain: Pilbara Minerals’ Dale Henderson on Today’s Lithium Paradox

June 28, 2025
Platinum Price Surges to 11 Year High, Breaks US$1,400

Platinum Price Surges to 11 Year High, Breaks US$1,400

June 28, 2025
Freegold Ventures Limited – Results of the Annual General and Special Meeting

Freegold Ventures Limited – Results of the Annual General and Special Meeting

June 28, 2025
  • About us
  • Privacy Policy
  • Terms & Conditions
  • About us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 revenueagenda.com | All Rights Reserved

No Result
View All Result
  • Investing
  • Latest News
  • Editor’s Pick
  • Economy

Copyright © 2025 revenueagenda.com | All Rights Reserved